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The gene for glutathione-S-transferase (GST) M1 (GSTM1), a member of the GST-superfamily, is widely
studied in cancer risk with regard to the homozygous deletion of the gene (GSTM1 null), leading to a lack of
corresponding enzymatic activity. Many of these studies have reported inconsistent findings regarding its
association with cancer risk. Therefore, we employed in silico, in vitro, and in vivo approaches to investigate
whether the absence of a functional GSTM1 enzyme in a null variant can be compensated for by other family
members. Through the in silico approach, we identified maximum structural homology between GSTM1
and GSTM2. Total plasma GST enzymatic activity was similar in recruited individuals, irrespective of their
GSTM1 genotype (positive/null). Furthermore, expression profiling using real-time PCR, western blotting,
and GSTM2 overexpression following transient knockdown of GSTM1 in HeLa cells confirmed that the
absence of GSTM1 activity can be compensated for by the overexpression of GSTM2.
G
lutathione-S-transferases (GSTs) belong to a superfamily of ubiquitous, multifunctional dimeric cyto-
solic enzymes that play a very important role in the Phase II detoxification (or biotransformation)
pathway in humans and confer protection against a wide array of toxic insults1,2. Several GST isoforms
have been identified and characterised, forming seven distinct classes: a, m, p, o, t, k, and f3,4. Functionally, most
GSTs catalyse the conjugation of the nucleophilic tripeptide glutathione to a wide range of electrophilic substrates
for detoxification. However, the conjugation reaction can occasionally lead to the formation of compounds that
are far more toxic than the initial substrate, thereby leading to disease outcomes1,5,6. Interestingly, a null variant is
encountered for two members, GSTT1 and GSTM1, whereby the entire gene is homozygously deleted in a
considerable proportion of different populations, resulting in the complete absence of the corresponding enzyme
activity7,8. The GSTM1 gene is highly polymorphic and is located on chromosome 1p13.3. A wide range of
variation in GSTM1 homozygous deletion polymorphism (approximately 20–67%) has been observed globally
with regard to various ethnicities9–12. It is often hypothesised that, due to the lack of functional GSTT1 and/or
GSTM1, the null phenotype is unable to efficiently perform the conjugation reaction (biotransformation) and the
subsequent elimination of toxic products via urine and bile. The null variant ofGSTM1 is of particular interest, as
a plethora of studies have demonstrated the difference in susceptibility, exposure to environmental toxicants,
resistance to chemotherapy treatment, variability in drug response, manifestation of several diseases, and, most
importantly, cancerous outcomes.
The four othermembers of the GSTm subfamily, i.e.,GSTM2,GSTM3,GSTM4, andGSTM5, exhibit high levels
of sequence homology and substrate specificity with GSTM113. Among these genes, GSTM1 has largely been
studied due to its null genotype. Although a large number of studies have attempted to associate theGSTM1-null
genotype with cancer risk, the results are inconclusive. Several studies have attempted to identify the association
ofGSTM1 null with cancer risk throughmeta-analysis using the existing literature; however, these analyses failed
to show a significant association of GSTM1 with cancer14–20. These observations prompted us to search for the
functional relevance of this ‘‘well known gene’’ with other family members that are relatively less studied. A
possible explanation of the apparently inconsistent results could be that other members of the GST family
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the other members of the GST family, particularly those belonging to
the GSTM group, can compensate for the loss of the GSTM1 enzyme
due to the absence ofGSTM1 under normal physiological conditions.
Results
GSTM1 sharesmaximumhomology withGSTM2. In our structural
homology analysis, the members of the GST superfamily were found
to share high sequence homology with each other when examined by
ClustalW (http://www.genome.jp/tools/clustalw/) and a domain
search using Pfam (http://pfam.sanger.ac.uk). Members of the
same class (i.e., other GSTm enzymes) share 75–99% sequence
identity (maximum homology between GSTM1 and GSTM2),
whereas the homology is approximately 25–30% with different
classes (GSTh and GSTp). This finding prompted us to perform a
3D superimposition of the GSTM1 protein structure with other
members of the GSTm family, GSTT1, and GSTP1 through
Research Collaboratory for Structural Bioinformatics Protein Data
Bank (RCSB-PDB). The results distinctly demonstrated that GSTM2
has the highest degree of identical 3D organisation with GSTM1
(root-mean-square deviation [RMSD] value of 0.7 A˚). In addition,
the enzyme expression pattern from the GeneCard database (http://
www.genecards.org/) also suggests a similar pattern of expression
among the family members, with maximum similarity in
expression patterns in the case of GSTM1 and GSTM2 in different
tissues.
Similar GST enzymatic activities in GSTM1 null and non-null
groups. We recruited 275 healthy individuals for screening the
GSTM1-null variant. Among the 275 individuals initially recruited,
68 (24.73%) were found to have a GSTM1-null (homozygous
deletion for GSTM1) genotype; the remaining 207 (75.27%)
individuals were positive for GSTM1 (had at least one functional
GSTM1 allele). The null group was composed of 18 female and 50
male individuals; 36 female and 100 male participants were selected
from the 207 GSTM1-positive individuals (matched in terms of age,
gender, and tobacco usage to nullify possible confounding factors)
for further studies. We measured the total plasma glutathione S-
transferase enzymatic activity level in the GSTM1-null and
-positive individuals. However, the detection of the actual GSTM1
concentration is difficult due to the limitations of antibody-based
detection methods and high cross-reactivity among members of
the GSTm subfamily; thus, we measured the total plasma GST
activity. For this purpose, a non-fluorescent dye, monochlorobi-
mane (MCB), was used. No significant difference was observed in
the overall plasma GST activity between the GSTM1-null and
-positive individuals (Fig. 1). In other words, the GSTM1-null
individuals exhibited the same catalytic efficiency for MCB as the
GSTM1-positive individuals.
Overexpression of GSTM2 in GSTM1-null individuals. Real-time
PCR was performed to explore the contribution of other GST family
members compensating for GSTM1 activity in null individuals in
vivo. We evaluated the expression pattern of several members of the
GST family (GSTM1-GSTM5, GSTT1, and GSTP1) in presence or
absence of GSTM1. For this purpose, 15 age, sex, and tobacco usage-
matched individuals were selected from both the GSTM1-positive
and -null groups, and the gene expression levels of the seven
aforementioned GST members were examined. A two-step quanti-
tative real-time polymerase chain reaction (qRT-PCR) approach was
implemented using SYBR-Green I. The preliminary results indicated
that GSTM2 was expressed at an approximately 2.4-fold higher level
in the lymphocytes of GSTM1-null individuals compared to the
GSTM1-positive individuals; however, no significant difference was
observed in the case of the other GST enzymes (Fig. 2). We also
measured the expression pattern of GSTM1 and GSTM2 in the
lymphocytes of the GSTM1-positive and -null individuals by
western blotting and found that expression of the GSTM2 protein
was considerably higher (,2-fold) in the GSTM1-null individuals
compared to the GSTM1-positive individuals (Fig. 3).
Restoration of cellular function byGSTM2 inGSTM1-null indivi-
duals. To verify the observed compensatory role of GSTM2 in the
absence of GSTM1, a cell culture-based approach was employed. We
used green fluorescent protein (GFP)-tagged plasmid constructs of
GSTM1 and/or GSTM2 in HeLa cells and evaluated the capacity of
the transfected cells to cleave the glutathione-sulphoraphane (GSH-
SF) conjugate, an isothiocyanate intermediate that is naturally
produced in the body during post-digestion, is normally broken
down to free sulphoraphane (SF) by the catalytic action of
GSTM121. Sulforaphane induces cell death, mainly through apop-
tosis, by acting as a growth inhibitor in such cancer cell lines as
HeLa and HT2922–24. However, it is not known, whether the
GSTM2 enzyme can perform a similar function. Indeed, if the
GSTM2 enzyme catalyses the breakdown of this conjugate in a
manner comparable to that of GSTM1, the functional similarity
between these two isozymes would be established. It is known that
HeLa cells express only basal levels of GSTM1, but not GSTM225.We
over-expressed GSTM1 and GSTM2 in HeLa cells following the
transient knockdown of GSTM1 by siRNA. The breakdown of the
GSH-SF conjugate and subsequent release of free SF in each case was
estimated from the percentage of cell death, as measured by a trypan
blue exclusion assay26. The level of expression ofGSTM1 andGSTM2
in each case was confirmed by western blotting of whole-cell lysates.
The death rate of the cells in the presence of the GSH-SF conjugate
either with GSTM1 or GSTM2 (over the background of GSTM1
knockdown) was similar (Fig. 4). This result clearly demonstrated
that both GSTM1 and GSTM2 had the same functional efficiency. In
other words, GSTM2 could effectively compensate for the loss of
GSTM1 under physiological conditions.
Discussion
The majority of polymorphisms found to affect genes involved in
carcinogenesis are single-nucleotide polymorphisms. In contrast, the
complete absence of a function in the form of null allele is relatively
rare; thus, the GSTM1 homozygous deletion genotype has attracted
much attention of researchers worldwide. Extensive studies have
Figure 1 | Total plasma GST activity in the GSTM1-positive and -null
groups. The total plasma enzyme activity (mean 6 SEM, in
mU.mg21.min21) was found to be similar in both groups, though GSTM1
isoenzyme activity should be undetectable in the GSTM1-null individuals.
The similar level of total plasma GST activity indicates the presence of a
counter-balance mechanism.
www.nature.com/scientificreports
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been attempted to link the GSTM1-null genotype with disease,
particularly cancer. However, the results of association studies cor-
relating GSTM1 with disease risk have been inconclusive, and
numerous studies, including a large number of meta-analysis
reports, have failed to demonstrate a significant association14,16,17. A
meta-analysis of 98 case-control studies was conducted to test the
association of GSTM1 null with lung cancer risk, revealing a poor
association in both random and fixed effect models; however, no
increase risk was seen when only the five largest studies (.500 cases
each) were considered27. Analysing 130 case-control studies on
GSTM1 null with lung cancer risk revealed a similar observation15.
GSTM1 is highly polymorphic, and the prevalence of the GSTM1-
null genotype in different populations ranges from 64% to as high as
100% in Kiribati natives28. The frequency also suggests that this gene
Figure 2 | Gene expression profiling of GST enzymes. Normalised gene expression profile (mean 6 SEM) for GST family members in 15 GSTM1-null
individuals with respect to the 15 age and sex-matched GSTM1-positive individuals. The significantly high GSTM2 expression (2.4 fold) under
normal physiological conditions indicates a compensatory mechanism in the individuals completely lacking the GSTM1 enzyme.
Figure 3 | Western blot analysis reveals high GSTM2 expression in the GSTM1-null individuals. Representative figure for (a) b-actin from oneGSTM1
positive (Lane 1) and two null individuals (Lanes 2 and 3). (b) AGSTM1-positive individual showing a specific 26-kDa band forGSTM1, whereas no band
is observed for the GSTM1-null individuals. (c) GSTM2 is present in all three individuals, though with various intensities. (d) A densitometric
analysis (mean 6 SEM; pixels/ng) of the target proteins in the western blot. A total of 17 GSTM1 null and 16GSTM1 positive samples were analyzed. All
the blots are representative cropped images and every set have been processed simultaenously, under similar conditions. Representative original blots with
cropped demarcations (3b & 3c) are provided in supplementary figure 1.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 2704 | DOI: 10.1038/srep02704 3
has not encountered strong environmental selection pressure during
evolution and that there might be other enzymes involved in similar
chemical detoxification. Based on the results of association studies, it
can be clearly understood thatGSTM1, a low-penetrant gene, is not a
major determinant for cancer association. However, cancer risk can
bemodulated due to this polymorphism. Therefore, it is important to
test the predictive value of the GSTM1-null variant before popu-
lation-based association studies are conducted. Accordingly, in the
present study, we attempted to highlight the role of other family
members, particularly in the absence of a functional GSTM1 allele.
Although no enzyme activity is expected in individuals with a null
genotype. There are some interesting observations in which GSTM1
activity was identified in GSTM1-null individuals, though the
authors failed to present any supportive evidence29,30. These findings
support our observation of the total GST activity being similar in
individuals, irrespective of the presence or absence of GSTM1. This
situation is possible only if another member of the GST family com-
pensates for the loss of GSTM1 in the null individuals. In our study,
the enhanced expression of GSTM2, both at the mRNA and protein
level, confirmed the role of a compensatory mechanism by a family
member in the absence of GSTM1. Moreover, our in vitro functional
assays clearly demonstrated a rescue of catalytic activity towards
Glutathione-sulforaphane breakdown by GSTM2 over expression
in cells where GSTM1 was knocked down. Taken together, these
observations, i.e., structural and functional, strengthen our hypo-
thesis of the compensatory role of GSTM2 in the absence of a func-
tional GSTM1 gene. Therefore, a new assessment of the association
studies connecting the GSTM1-null phenotype with disease incid-
ence is required, and such studies must be supplemented with func-
tional proof to substantiate their findings. In addition, we might also
extrapolate the results of this study to hypothesise that, while study-
ing a disease involving a gene family with high sequence homology
and overlapping substrate specificity, the examination of only one
gene will not provide the proper insight of the disease in question, as
multiple numbers of gene families can function simultaneously.
Methods
Study samples. Healthy study participants were selected from the East Midnapore
district, West Bengal, India. We collected blood samples (approx. 5 ml each) from
275 individuals (ages between 15 and 70 years). All the participants were recruited
after a thorough screening by physicians, and each provided informed consent before
they were included in the study. The non-physician interviewer examined the
participants on the basis of a structured questionnaire that elicited information about
their lifetime residential history, occupation, diet, and smoking habit. This study was
conducted in accord with the Helsinki II Declaration and approved by the ethics
committee of CSIR-Indian Institute of Chemical Biology.
Isolation of plasma, DNA, RNA, and protein. Blood samples were centrifuged at
1000 3 g for 10 minutes at 4uC to isolate plasma. Nucleic acids and proteins were
isolated from blood using the Qiagen DNA, RNA, protein isolation kit following the
Figure 4 | Evidence for the functional similarity of the isozymes GSTM1 and GSTM2. Group (a): i) Trypan blue cell viability assay for GSTM1 in HeLa
cells. ii)Western blotting analysis of GSTM1 overexpression in transfected (C) and control cells (V). iii) GFP profile in transfected HeLa cells. Group (b):
i) Trypan blue cell viability assay of HeLa cells transfected with GSTM2 and treated either with scrambled or GSTM1-targeted si-RNA (V-, empty vector
without GSH-SF treatment, V1, empty vector with GSH-SF treatment, C-, plasmid construct with either GSTM1 (in figure a) or GSTM2 (in figure b)
without GSH-SF treatment, C1, plasmid construct with GSH-SF treatment). ii)Western blotting analysis of GSTM1 in the siRNA-treated HeLa cells. iii)
Western blot analysis of GSTM2 in siRNA-treated HeLa cells. iv) GFP profile of transfected HeLa cells after siRNA treatment. All the blots are
representative cropped images and every set have been processed under similar conditions as detailed in the methods section.
www.nature.com/scientificreports
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manufacturer’s protocol (Qiagen, Hilden, Germany). The concentration and quality
of the nucleic acids were measured using a NanoDrop instrument (NanoDrop
Technologies, Wilmington, DE, USA) and agarose gel electrophoresis. The protein
concentration was determined using the standard protocol of Bradford (Amresco,
OH, USA) assay using bovine serum albumin (HiMedia, India) as a standard; the
specific enzyme activity was expressed in mUmg21min21.
Screening ofGSTM1-null samples. For identifying and confirming the GSTM1-null
variant, two exons (exon 2 and exon 7) were amplified separately31. To ensure that the
absence of PCR products for any template was due to the presence of a null mutation
and not the result of amplification failure, GSTM2 exon 1 (FP, 59-
CTGTCTGCAGAATCCACAGC-39, and RP, 59-CTGCAGCTGCTCCACACTT-39)
was amplified as a positive control. Cycling was performed using an Eppendorf
Mastercycler (Hamburg, Germany), as follows: a pre-PCR step of a 5-min
denaturation at 94uC, followed by 30 cycles of denaturation at 94uC for 30 sec,
annealing for 30 sec, and extension at 72uC for 30 sec, and a final 5-min incubation at
72uC; the annealing temperature was 69uC (for M1_exon 2) or 58uC (for both
M1_exon 7 andM2_exon 1). All PCR products were separated by polyacrylamide gel
(6%) electrophoresis, stained with ethidium bromide, and photographed under UV
light.
Total plasma GST enzyme activity assay. The total plasma GST enzyme activity was
measured using the Bio-Vision Fluorometric activity assay kit (CA, USA) following
the manufacturer’s protocol. Monochlorobimane (MCB), a non-fluorescent
substrate, was used; MCB fluoresces blue upon reaction with glutathione, and the
level of fluorescence is directly proportional to the enzyme activity. The fluorescence
was quantified using a micro-plate fluoro-spectrometer (LS 55, Perkin Elmer) at Ex/
Em of 380/460 nm32. The plasma protein concentration was estimated using the
Bradford assay, as described above, prior to the enzyme activity analysis.
Expression profile of the GSTM group using real-time PCR. A two-step qRT-PCR
approach was considered using SYBR-Green I (Brilliant SYBR Green QPCR master
Mix, Agilent Technologies, CA, USA). Total RNA (1 mg) isolated from each sample
was treated with DNase I (Applied Biosystems, Foster City, CA) prior to cDNA
synthesis using theMMuLV-based reverse transcriptase enzyme (RevertAidHMinus
First strand cDNA synthesis kit, Fermentas Life Sciences, USA). Primers were
designed for the exon-exon boundary using Primer 3 software, and the b-actin gene
was used as an internal control (Table 1). Each sample, in duplicate, was amplified as
follows: one cycle of 95uC for 1 minute for pre-incubation, followed by 40 cycles of
95uC for 30 seconds, 60uC for 1 min, and 72uC for 1 minute, with a subsequent
melting curve analysis using Mx3000p (Stratagene, Agilent Technologies, CA, USA).
In addition, after qRT, the amplified product was further analysed by PAGE. An
efficiency correction was performed using Agilent software. The fold change in the
target gene expression in the GSTM1-positive versus the GSTM1-null samples was
calculated using the formula 2-DDCT following the general guidelines discussed by
Schmittgen and Livak33. The fold difference was calculated after the data were
normalised with the internal control. A less than 0.5 fold change was considered to be
under-expression, whereas a. 2.0-fold increase was considered to be overexpression.
Western blotting. Protein lysates were prepared using 1% sodium dodecyl sulphate
(SDS) lysis buffer and resolved by 12.5% SDS-PAGE for 2 hours at 150 mA, followed
by dry transfer (i-Blot protein transfer apparatus, Invitrogen, USA) and incubation
with primary antibodies. Rabbit anti-human GSTM1 antibody (Upstate
Biotechnology, Lake Placid, NY, USA), rabbit anti-human GSTM2 antibody
(Lifespan Biosciences, Inc, Seattle, WA) and rabbit anti-human beta-actin antibody
(Santa Cruz Biotechnologies, CA, USA) were used in 151000 dilutions, followed by
goat anti-rabbit IgG (GE Healthcare) as the secondary antibody (152000 dilutions).
Cell culture and transfection. HeLa cells were obtained from the national cell
repository of the National Center for Cell Science (Pune, India). GFP-tagged plasmid
constructs for GSTM1 and GSTM2 were purchased from OriGene Technologies Inc.
(Rockville, MD, USA). The plasmids were propagated in E. coli DH5alpha and
purified using Qiagen plasmid purification kits (Qiagen, Valencia, CA, USA). A 20-
mM stock solution of the GSH-SF conjugate (USBio, Swampscott, MA, USA) was
prepared in molecular-grade water (Invitrogen, Carlsbad, CA, USA) and stored at
220uCuntil use.Water was used as vehicle/control for theGSH-SF treatment. Empty
GFP vector and scrambled siRNAwere used as the control for the overexpression and
knockdown experiments, respectively. For GSTM1 knockdown, HeLa cells were
transfected with scrambled or GSTM1 siRNA (Dharmacon Inc., USA) using the
Dharmafect-1 transfection reagent according to manufacturer’s instructions. At
72 hours post-RNAi GSTM2 transfection (over the background of GSTM1
knockdown) was carried out with GSTM2 or control plasmids using Lipofectamine
LTX (Invitrogen, Carlsbad, CA, USA) reagent according to the manufacturer’s
protocols34. At 48 hours post-GSTM2 transfection, the expression efficiency was
estimated to be , 80%, as based on GFP reporter expression. The cells were serum
starved overnight and were treated with 15 mM GSH-SF or vehicle for additional
48 hours22. Post-treatment, cell viability was then assessed by trypan blue exclusion
assay using a Neubauer haemocytometer under an inverted bright- field microscope
(Leica Microsystems, GmbH, Germany). The data represent the total counts of 200
cells, expressed as percentage, from each group across three independent
experiments.
Statistical analyses. All the data are expressed as the mean 6 S.E. The statistical
analyses were performed with the Mann–Whitney test or Student’s t-test, as
applicable. GraphPad was used for the analyses.
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